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Previous studies have shown that a loss of GABAergic neuronal somata is associated with a loss of GABAergic terminals at chronic 
cortical epileptic foci in monkeys. The present study was undertaken to determine whether GABAergic neuronal oss occurs prior to 
the onset of clinical seizures in monkeys that were treated with alumina gel but did not display seizures. Seven adolescent (Macaca mu- 
latta) monkeys received alumina gel implants into the left pre- and post-central gyri, specifically centered in hand-face regions of sen- 
sorimotor cortex. Three other monkeys were used as controls. Two of these were surgical controls and the third was a normal animal. 
Three monkeys (pre-seizing) were sacrificed 2-4 weeks after the alumina gel implant but prior to clinically active seizures. Three 
other monkeys with chronic seizure activity (chronically seizing) were sacrificed 3-6 months after the implant. Tissue sections were 
taken from an area adjacent o the alumina gel granuloma (focus), from a site distal to it (parafocus) and from the non-epileptic ontra- 
lateral side. Sections from all monkeys were processed for glutamate decarboxylase (GAD) immunocytochemistry and then examined 
with a light microscope. In addition, adjacent sections were stained with a Nissl stain and the total number of neurons was counted in 
these sections. Statistical analysis howed a significant decrease in the number of GAD-positive cells in the pre-seizing and chronic ani- 
mals. The pre-seizing monkeys showed a significant loss of 23-44% at the focus in contrast o the total number of neurons which did 
not change significantly, The loss of GAD-positive cells was greater in the chronic animals that showed significant losses at both the fo- 
cus and parafocus, 42-61% and 15-26%, respectively. It is important to note that the chronic monkeys displayed an ll-61% signifi- 
cant loss of total neurons at the epileptic focus. The surgical control animals showed no seizure activity and no significant loss of total 
neurons or GAD-positive cells. The main finding of this study indicates that a selective loss of GAD-positive neuronal somata occurs 
in pre-seizing monkeys with alumina gel implants. This finding is consistent with the previously reported loss of GABAergic terminals 
in pre-seizing monkeys. Since virtually all monkeys treated with alumina gel develop seizures, the results of this study add further sup- 
port to the hypothesis that GABA neuronal oss plays a causal role in focal epilepsy. 
INTRODUCTION 
Experimental models of focal epilepsy have 
been examined for specific cellular and biochemi- 
cal changes to obtain an understanding of certain 
types of human epilepsy 1,2,4.10~13,21,24, The alumina 
gel model in monkeys is an excellent model of 
post-traumatic epilepsy in humans13. Also, this 
model best approximates the histology of human 
Correspondence to: Dr. Charles E. Ribak, Department of 
Anatomy and Neurobiology, University of California, Irvine, 
Irvine. CA 92717, U.S.A. 
foci in that they are both characterized by neuro- 
nal loss, reactive gliosis, and dendritic abnormali- 
ties3*55’5,‘8,25,26. Seizures usually begin 2-3 months 
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following the alumina gel implants into the hand 
region of the sensorimotor cortex. This model has 
been analyzed with biochemical, anatomical, phys- 
iological, and pharmacological methods. Epilep- 
tic monkeys with alumina gel implants display 
spike and wave activity on electroencephalograms 
(EEGs) and electrocorticograms (ECoGs) which 
arises from the site adjacent to the alumina granu- 
loma and a surrounding area of cortex2’. Excision 
of these two regions abolishes epileptic activity6. 
In addition, extracellular recordings from cells in 
the focus display abnormal excitatory post-synap- 
tic potentials2’. 
A growing body of evidence indicates that neu- 
rons containing the neurotransmitter gamma- 
aminobutyric acid (GABA) are preferentially lost 
in the epileptic foci of monkeys treated with alumi- 
na gel. Binding studies of these monkeys have in- 
dicated a decrease in the number of GABA recep- 
tors and biochemical studies have demonstrated a 
loss of tissue GAD activity in the focus’. Con- 
sistent with these findings were the initial immuno- 
cytochemical data that demonstrated a 58-62% 
loss of GABAergic axon terminals in the epileptic 
focus of chronically seizing monkeys that had not 
reached status epilepticusig. Subsequent studies 
have indicated that greater than 80% of the axon 
terminals of GABAergic chandelier and basket 
cells have degenerated at epileptic foci’7,‘8. More 
recent immunocytochemical studies have shown 
that the loss of these terminals at chronic epileptic 
foci was due to a loss of GABAergic somata2’. 
However, it was not shown whether a significant 
loss of GABAergic somata precedes the onset of 
seizure activity because only one pre-seizing mon- 
key was used in that study2’. This question needs 
to be resolved because recent findings have shown 
a loss of GABAergic terminals prior to the onset 
of clinical seizures’. Therefore, the present study 
of alumina gel-treated monkeys was undertaken 
using a larger number of pre-seizing monkeys to 
determine whether a significant loss of GABAer- 
gic somata occurs prior to the onset of seizure ac- 
tivity. Additional monkeys with chronic epilepsy 
were also studied. Finally, Nissl-stained sections 
from all monkeys were analyzed to determine the 
effect of alumina gel-induced seizures on the total 
number of cortical neurons. These latter data 
would determine whether the loss of GABAergic 
somata was selective. 
MATERIALS AND METHODS 
Ten adolescent monkeys (Macaca mulatfu) were 
used in this study. Two of the monkeys (RB 160 
and 161) were used in a previous study2’. The 
monkeys weighed from 3 to 5 kg, were neurolog- 
ically normal, and had normal initial scalp EEGs. 
The animals were housed in a controlled environ- 
ment, in individual cages, under the care and su- 
pervision of veterinarians who specialize in the 
care of non-human primates. 
Under general anesthesia, 9 of the monkeys un- 
derwent a left frontoparietal craniotomy. The pre- 
central (Brodmann’s area 4) motor cortex for the 
hand-face area was identified by electrocortical 
stimulation. Seven monkeys (RB-160, 161, 175, 
176, 180, 184, 185) were injected with 0.2 ml of 
aluminum hydroxide (alumina gel) into the left 
pre- and post-central gyri using the Ward modifi- 
cation of the Kopeloff technique12. Two monkeys 
(RB-182 and RB-183) were used as surgical con- 
trols in which a subpial resection was made of a 5 X 
5 mm area down to the white matter. This area is 
approximately equivalent to the area of a mature 
alumina granuloma. One monkey (RB-179) re- 
ceived neither an injection of alumina gel nor a 
surgical esion and served as a control animal. 
Postoperatively none of the animals received an- 
ticonvulsants. All animals were clinically observed 
on a daily basis for seizures. In addition, weekly 
scalp EEGs were performed postoperatively on all 
monkeys until the time of sacrifice except for 2 
monkeys (RB-184 and RB-185) that had subdural 
electrodes placed for ECoG monitoring on a 
weekly basis. The electrophysiological changes, in 
large part, determined the time when anatomical 
changes were investigated. Chronic seizure mon- 
itoring was similar to that previously recorded’. 
Three monkeys (RB-161, 175, 176) were sacri- 
ficed 2-4 weeks post-injection time which was 
prior to the development of seizure activity (Table 
I). These animals are referred to as pre-seizing 
monkeys and, although they did not display sei- 
zures, they demonstrated a sharp wave activity ad- 
jacent to the granuloma on the ECoG. The acute 
128 
seizing monkey (RB-160) was sacrificed 6 weeks 
following the injection. This animal displayed 2-3 
seizures/day for 4 days. The fifth monkey (RB- 
179) was a normal control animal which displayed 
a normal ECoG. The sixth monkey (RB-180) dis- 
played 3 seizures/week and was sacrificed 3 
months following the alumina gel injection. The 
seventh monkey (RB-184) was sacrificed 5 months 
post-injection time and displayed 1 seizure/week. 
The last of the chronically seizing monkeys (RB- 
185) exhibited 1 seizure/week and was sacrificed 
6.5 months following the injection. These chroni- 
cally seizing animals showed an ECoG consistent 
with spike and wave discharges in the area im- 
mediately adjacent to the developing granuloma. 
Two other animals (RB-182, 183) that were surgi- 
cal controls were sacrificed 2.5 months after the 
surgical lesion procedure and demonstrated no 
ECoG abnormalities. 
After the ECoG, each monkey was anesthetized 
with sodium phenobarbital and perfused transcar- 
dially with approximately 2 liters of a 0.2% para- 
formaldehyde solution so that receptor studies 
could be made on the same brains. The skull and 
dura were removed after the perfusion. A tissue 
block from the left precentral gyrus was immedi- 
ately removed and included an area adjacent to 
the alumina gel injection and an area l-2 cm su- 
perior to the injection site. A block of tissue was 
also taken from the right precentral gyrus to be 
used as control tissue. These blocks were placed in 
a 10% formalin solution for further fixation. The 
tissue was then placed in a cryoprotectant solution 
of 30% sucrose in phosphate-buffered saline 
(PBS) for 24 h. Sections of 40 ,um thickness were 
cut on a freezing microtome and placed in 0.1 M 
PBS for light microscopic immunocytochemistry. 
Free floating sections were processed for the im- 
munocytochemical ocalization of glutamic acid 
decarboxylase (GAD), the synthesizing enzyme 
for GABA, using an anti-GAD serum developed 
by Oertel et al.“. Sections from the right and left 
hemispheres were incubated at the same time. A 
modification of Oertel’s protocol was used em- 
ploying the avidin-biotin-horseradish peroxidase 
complex (Vector Labs.)‘. Briefly, the sections are 
incubated in 0.1 M D,L-lysine in 10% normal rabbit 
serum for 12 h and then incubated in the primary 
TABLE I 
Survival time vs. seizure activity of 10 monkeys (Macaca mulat- 
tal 
._~. ..I ..__._. __~~~_.~_,_~~~~~-“~~~~~~~~ 
Animal Alumina Survival Seizure 
gel time * activity * * 
RB-161 pre-seizing f 1 
RB-175 pre-seizing + I 
RB-176 pre-seizing + 0.5 - 
RB-160 acute + 1.5 + 
RB-180 chronic + 3.0 +++ 
RB-184 chronic t- 5.0 i 
RB-185 chronic + 
RB-179 normal - 
RB-182sham*** - 
RB-183 sham*** _ 
* Survival time in months. 
** + equals 1 seizure/week. 
‘” ** Surgical controls. 
6.5 + 
2.5 - 
2.5 - 
antiserum raised in sheep against GAD for 24-28 
h. Following three 10 min rinses in T&buffered 
saline (TBS), the sections are incubated in the bio- 
tinylated secondary antibody, rabbit antisheep 
IgG (1:227) for 45 min. After 3 more 10 min rinses 
in TBS, the sections are then incubated for 45 min 
in a mixture of avidin and biotinylated peroxidase 
complex (1: 114). Following 3 additional rinses in 
TBS, the sections are reincubated with the secon- 
dary antibody for 30 min, rinsed again in TBS and 
reincubated in the avidin biotinylated peroxidase 
complex for 30 min. After another 3 rinses in TBS, 
the sections are reacted for 15-30 min in a DAB 
solution (6 mg diaminobenzidine/lO ml TBS + 
0.002% hydrogen peroxide). Following three 10 
min rinses in TBS, the sections were then mounted 
on subbed.glass slides and air dried. These sections 
were then defatted in 50% chloroform and placed 
in alternating solutions of 0.0005% osmium tet- 
roxide and 0.05% of thiocarbohydrazide to inten- 
sify the reaction product. The tissue was then de- 
hydrated and coverslipped. 
Sections of tissue were examinea under a light 
microscope equipped with a 40 x objective lens. 
All sections were analyzed for the content of 
GAD-positive cells. The GAD-positive cells were 
identified as cells with dense, brownish reaction 
product within their perikaryal cytoplasm. The 
alumina gel-treated animals (Table I) were exam- 
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Fig. 1. Lig :ht photomicrographs of GAD-immunoreacted sections from a pre-seizing alumina gel-treated monkey (m-161). 1 1 shows 
the PaI nafc ICUS where a number of GAD-positive cells (arrows) are found in Iayer V of motor cortex. Two large pyramidal cells tt iat are 
non -irr tmu moreactive are apposed by numerous GAD-positive puncta (arrowheads). B shows the focus from this same monke :Y . Note 
that th ere are less GAD-positive cells (arrows) as well as puncta (arrowheads) adjacent o pyramidal cells as compared to the P iarafo- 
cus. The contralateral non-epileptic site (not shown) was similar to the parafocus. Bar = 25,um. 
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ined and counted for GAD-positive cells at 4 sites. 
The area adjacent to the alumina granuloma was 
referred to as the focus, whereas an area 1 cm from 
the focus was called the parafocus. Two other sites 
were examined for these monkeys, and they were 
located in the contralateral hemisphere. The 2 sur- 
gical control animals were examined at a proximal 
site adjacent to the lesion, at a distal site about 1 
cm away from the lesion, and at 2 other sites on the 
contralateral side. The normal monkey was 
counted for the number of GAD-positive cells at 2 
sites 1 cm apart in both right and left motor cor- 
tices. A grid reticule that covered a space which 
was 282 pm wide was used to count the number of 
GAD-positive somata. Three adjacent traverses 
were made through the entire thickness of the cor- 
tex. In addition, other sections through the motor 
cortex were stained with Cresyl violet, a Nissl 
stain. They were used to assess the total number of 
neurons at each site for every monkey by counting 
those neurons with nuclei in the section. Neuronal 
nuclei were distinguished from those of neuroglial 
cells by their sizes and morphologies. 
The 10 animals were examined by statistical var- 
iance testing to determine if there were differ- 
ences among the number of somata counted 
(Tables II and III). These animals were separated 
into 5 groups classified as normal, surgical control, 
pre-seizing, acutely seizing, and chronically seiz- 
ing. Each group contained 4 subgroups that were 
also compared. The pre-seizing, acute, and chron- 
ically seizing animals had 4 subgroups called the 
focus, parafocus, and contralateral one and con- 
tralateral two sites (Table II). The normal animal 
had 2 subgroups on the ipsilateral side and 2 on the 
contralateral side. The surgical control animals 
had proximal, distal, and 2 contralateral sub- 
groups. Then, a l-way analysis of variance 
(ANOVA) was used to determine if there were 
any significant differences among the interactions 
between groups for each of two sites (i.e., focus 
and parafocus). Post hoc testing was used to deter- 
mine specific between-group differences. 
RESULTS 
Qualitative description 
All layers of the normal and non-epileptic motor 
TABLE II 
Results of GAD-positive cell counts from 10 monkeys (number 
of somata10.795 mm2) 
RB-176 (pre-seizing) 
Focus 
Parafocus 
Cont. 
Cont. 
RB-160 (acute) 
Focus 
Parafocus 
Cont. 
Cont. 
RB-179 (normal) 
1st site 20.5 
2nd site 20.5 
Cont.* 23.3 
Cont. 24.6 
RB-182 (surgical control) 
Proximal to lesion 19.2 
Distal to lesion 21.9 
Cont. 20.5 
Cont. 19.2 
RB-183 (surgical control) 
Proximal to lesion 10.9 
Distal to lesion 12.3 
Cont. 13.7 
Cont. 15.0 
RB-161 (pre-seizing) 
Focus 16.4 
Parafocus 21.9 
Cont. 20.5 
Cont. 21.9 
RB-175 (pre-seizing) 
Focus 17.8 
Parafocus 24.6 
Cont. 27.4 
Cont. 26.0 
RB-180 (chronic) 
Focus 
Parafocus 
Cont. 
Cont. 
21.9 
28.7 
38.3 
39.7 
13.7 
19.1 
16.4 
17.8 
15.0 
26.0 
35.6 
34.2 
13.7 
27.4 
34.2 
3.5.6 
28.7 
42.4 
49.2 
50.6 
RB-184 (chronic) 
Focus 
Parafocus 
Cont. 
Cont. 
RB-185 (chronic) 
Focus 
Parafocus 
Cont. 
Cont. 
* Cont. indicates the contralateral cortex. 
cortex contained GAD-positive cells that were, in 
general, homogeneously distributed throughout 
all layers. However, somewhat fewer immuno- 
reactive neurons occurred in layer I and the deep- 
er part of layer VI of the motor cortex as com- 
pared to the other layers. The GAD-positive cells 
contained a brown reaction product in their peri- 
karyal cytoplasm and rarely were their dendrites 
stained. Many of these neurons displayed eccen- 
trically placed nuclei. The shapes of the cell bodies 
were clearly non-pyramidal (Figs. 1 and 2). Thus, 
the GAD-positive somata were round, oval, tear- 
drop shaped, or fusiform shaped. 
The sizes of GAD-positive cells varied as simi- 
larly shown in previous studies’,*‘. Most of the so- 
mata in layer I were small whereas somata in the 
deeper layers displayed a wide variety of sizes. 
Fig . L. Light 
she ws layer 
ous G AD-p{ 
par aft ecus, a 
Csl ho\ us the 
photomicrographs of GAD-immunoreacted sections from a chronically seizing, alumina gel-treated monkey ( 
V in the contralateral non-epileptic site that contains a number of densely stained GAD-positive cells (arrows) 
xitive puncta (arrowheads). Some of the puncta are concentrated around a pyramidal cell. B is taken from la 
site 1 cm from the focus. The number of GAD-positive cells (arrow) and puncta (arrowheads) is less than that 
distribution of GAD-positive cells (arrow) in layer V of the focus adjacent o the alumina gel granuloma. Some 
itive puncta (arrowheads) are found adjacent o a non-immunoreactive pyramidal cell. Bar = 25ym. 
‘RB-184). A 
and numer- 
yer V in the 
found in A. 
: GAD-pos- 
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Small cells were found throughout all layers of the 
cortex. However, the average somal area for 
GAD-positive cells increased from the superficial 
to the deep laminae. 
GAD-positive somata that were found in the fo- 
cus and parafocus sites were similar in shape and 
size to those in the normal and non-epileptic corti- 
cal sites (Figs. 1 and 2). Also, they were distrib- 
uted throughout the cortical layers, However, re- 
duced numbers of GAD-positive somata occurred 
in these regions of chronically seizing monkeys as 
compared to the 2 sites examined in the contralat- 
era1 cortex (Fig. 2B and C). The pre-seizing mon- 
keys displayed reduced numbers of GABAergic 
neurons in the focus (Fig. 1B). The parafocus in 
these monkeys appeared similar to the contralat- 
era1 non-epileptic cortex. In addition to these ob- 
servations for GAD-positive somata, the focus in 
both pre-seizing and chronically seizing monkeys 
displayed a reduction in the number of GAD-posi- 
tive pun&a as compared to the contralateral cor- 
tex (Figs. IB and 2C). 
The Nissl preparations of normal and non-epi- 
leptic cortices revealed the typical lamination pat- 
terns of neurons in the motor cortex (Fig. 3B). A 
prominent feature of this region, the large pyrami- 
dal cell of Betz, was found in layer V (Fig. 4). The 
Nissl preparations of pre-seizing motor cortex ad- 
jacent to the alumina gel granuloma displayed the 
same features as that described above for normal 
and non-epileptic cortices (Fig. 3C). A slight neu- 
ronal loss was observed in the focus site of chroni- 
cally seizing monkeys, especially in layers II and 
III (Fig. 3A). In the monkey with the most fre- 
quent seizure activity (RB-180), an increased 
number of glial cells were observed and the num- 
ber of neurons was severely reduced. 
Quantitative analysis 
Multiple brain sections from each monkey were 
analyzed for the between-group comparisons 
using analysis of variance (ANGVA). The mean 
number of GAD-positive cells at each of 2 sites 
(focus and parafocus) was expressed as a percent- 
age of the contralateral cortex. Since the mean 
number of these neuronal somata in the 2 contra- 
lateral sites of each monkey did not differ statisti- 
cally (t = 0.274, P = 0.786), they were averaged 
TABLE III 
Results of N&t counts of neurons from IO rn~~ke~s ~number of 
somata~~.15~mm2~ 
Sample Procedure Right 
motor 
cortex 
Left 
motor 
cortex 
~_ . 
% change 
in left 
cortex 
RB-179 
RB-182 
RB-183 
RB-161 
RB-175 
RB-176 
RB-160 
RB-180 
RB-184 
RB-185 
Normal 
Sham 
Sham 
Pre-seizing 
Pre-seizing 
Pre-seizing 
Acute 
Chronic 
Chronic 
Chronic 
.-__-.- -... -_ 
117 115 -1.7 
131 119 -9.2 
121.5 95 -21.8 
89.5 90 +0.6 
175.8 160 -9 
141.4 129 -8.8 
98.5 93.5 -5.1 
131.5 51.5 -60.8 
131 107.5 -17.9 
127 113.5 -10.6 
___~~ ~.. __~._ _ ~_-.__- 
together to obtain a single value. The following 
statistical analysis of all 10 monkeys was based on 
these normalized values. 
For the pre-seizing monkeys, the site adjacent to 
the alumina gel application showed a significant 
decrease in the numbers of GAD-positive neu- 
ronal somata relative to the contralateral cortex 
(Fig. 5). This reduction in the number of GABA- 
ergic neurons at the ‘focus’ for the pre-seizing 
monkeys ranged from 23 to 44% (Table II). These 
quantitative results supported the qualitative find- 
ings described above. In contrast, the number of 
GAD-positive cells in the parafocus of pre-seizing 
monkeys showed a smaller percentage difference 
(Fig. 5). These differences were of interest be- 
cause normal and surgical control animals did not 
differ significantly in the numbers of GAD-posi- 
tive neuronal somata at the different counting sites 
(Table II). When compared to the pre-seizing 
monkeys, the chronically seizing monkeys showed 
a larger reduction in the numbers of GAD-positive 
neuronal somata at both the focus and parafocus 
(Fig. 5). The data for chronically seizing monkeys 
(Table II) indicated a loss of GABAergic neurons 
at the focus and parafocus ranging from 42 to 61% 
and 15 to 26%) respectively. 
A l-way ANOVA showed significant differences 
between groups for both the focus (F (4, 38) = 
19.4, P < 0.0~1~ and parafocus (F(4,38) = 4.0, P 
< 0.001). The post hoc analyses with the Fisher 
Probable Least Significant Difference test showed 
Fig. 3. Light photpmicrographs of Nissl-stained sections of motor cortex from the chronically seizing monkey shown in Fig. 2. A shows 
the focus adjacent o the edge of the alumina get granuloma (arrows). Layer I (I) is located at the top of this figure and the other corti- 
cal layers are indicated below it. B shows the contralateral motor cortex from the same monkey shown in A. The number and distribu- 
tion of neurons in A and B are similar. However, layers II and III display a slight loss of neurons in A as compared to B. Bar = 1OO~m. 
C shows an enlargement of layer V from the focus in A. Pyramidal neurons (arrows) in many sixes show a normal morphology 
(cf., Fig. 4). Bar = 25,um. 
Fig 
nor 
. 4. Light photomicrographs of Nissl-stained sections of layer V of the motor cortex from the contralateral non-epileptic (A) 
,mal (B) cortices. Both show pyramidal cells (arrows) in various sizes. A was from the same chronically epileptic monkey (RB. 
as shown in Fig. 3. B was from RB-179, a normal monkey. Bar = 25 urn. 
I and 
,184) 
60 
40 
20 
0 i 
n.s. 
N parafocus 
•a focus 1 l 
7 r 
Normal Preseizure Chronic 
Groups 
Fig. 5. Numbers of GAD-positive neurons as percentages of 
the non-epileptic, contralateral side of the monkey motor cor- 
tex. The chronic and pre-seizing groups were injected with alu- 
mina gel. The normal group included 2 sham-operated mon- 
keys that were assessed for GABAergic neurons at 2 sites prox- 
imal and distal to the lesion which was not an epileptic focus. A 
normal monkey was also included in this category. * Significant 
at PC 0.05 level; ns. = not significant. 
that the reduction in the number of GABAergic 
neurons at the focus of the pre-seizing monkeys 
was significant (P < 0.05), as compared to the 
sham-operated and normal monkeys. Also, the 
number of GABAergic neurons at the focus of 
pre-seizing monkeys was significantly less than 
that of chronically seizing monkeys (P < 0.05). 
There was no significant reduction in the number 
of GABAergic neurons at the parafocus of pre- 
seizing monkeys. The chronically seizing monkeys 
also showed a significant loss of GABAergic neu- 
rons at the focus (P < O.OS), and this was signifi- 
cant when compared to all other groups. In addi- 
tion, this latter group of monkeys showed a signifi- 
cant loss of GABAergic heurons at the parafocus 
(P < 0.05). None of the other groups of monkeys 
showed any significant loss of GABAergic neu- 
rons at the 2 sites. 
The Nissl counts were made in both the right and 
left motor cortices. The left motor cortex was 
either the site for alumina gel application or the 
sham surgery. It is interesting to note that the loss 
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TABLE IV 
Percentage loss of somata and terminals at alumina gel epileptic 
foci 
Terminal loss Ceil body loss 
Pre-seizing Chronic Pre-seizing Chronic 
Ribak et a1.19* - 58-62% - 
Houser et a1.s 14-22% 24-33% - 
Ribak et alzo - 35-52% 
Present study - - 23-44% 42-61% 
* Excluding the most chronic animal with status epilepticus. 
of total neurons in the pre-seizing and acute mon- 
keys at the focus site was similar to that found in 
the sham-operated monkeys (Table III). Statis- 
tical tests revealed no significant differences for 
these small reductions in cell number. In contrast, 
the 3 chronic monkeys displayed a significant loss 
of neurons that ranged from 11 to 61% (P < 0.05, 
Mann-Whitney U test). The monkey (RB-180) 
with the most severe loss of neurons was the same 
one that displayed the large increase in glial cell 
number (see above). 
DISCUSSION 
The major finding of this study is the demonstra- 
tion of a significant and selective loss of GABAer- 
gic somata at the focus site in the pre-seizing alu- 
mina gel-treated animals. The magnitude of the 
loss of GABAergic neurons was 23-44% as com- 
pared to the contralateral, non-epileptic cortex 
(Table IV). The magnitude of this significant loss 
contrasts with the non-significant percentage 
change of total neurons in the pre-seizing cortex 
that ranged from an increase of 0.6% to a loss of 
9% (Table III). Therefore, the loss of GABAergic 
neurons at focal sites of alumina gel application in 
pre-seizing monkeys is selective for this neuronal 
type. In addition, these data suggest hat GABA- 
ergic neuronal loss precedes the onset of clinical 
seizures, a finding that is consistent with the re- 
sults of Houser et al.‘, who showed a significant 
loss of GABAergic terminals in pre-seizing mon- 
keys. Since this latter study showed degenerating 
terminals at the electron microscopic level, it is 
likely that the reduction in the number of GAD- 
immunoreactive somata reflects a degeneration of 
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these neurons and not simply a loss of immuno- 
cytochemically detectable levels of GAD in corti- 
cal GABAergic neurons as observed in the 
kindling model of epilepsy”. The loss of GABAer- 
gic neurons in pre-seizing monkeys is probably a 
result of the alumina gel implants because the sur- 
gical control animals (Table II) did not show a sig- 
nificant loss of GABAergic neurons. Therefore, 
the alumina gel may somehow affect the cortical 
vascular supply to cause ischemia which may be 
the cause of the selective destruction of GABAer- 
gic neurons as previously proposed’81’2. 
Another important finding of this study was that 
the chronically seizing monkeys displayed a sig- 
nificant loss of GABAergic neurons at both the fo- 
cal and parafocal sites. A previous study showed a 
significant loss of GAD-positive cells at the fo- 
cus’“. However, the parafocal region in these same 
chronic monkeys did not show a significant loss?‘. 
This was probably due to the fact that those 
chronic animals were sacrificed 2-2.5 months af- 
ter the alumina gel implant. In the present study, 
the chronic animals were sacrificed 3-6.5 months 
after the implant. These data add support to an old 
adage, that seizures beget more seizures. In other 
words, the longer the time interval between im- 
plantation of the alumina gel and the time of exam- 
ination of brain tissue, the more seizures will have 
occurred and the more severe will be the degener- 
ation of GABAergic neurons and terminals. Thus, 
the results of the present study show that alumina 
gel causes a significant loss of GABAergic neu- 
rons prior to seizures at the focus and that as sei- 
zures progress, more GABAergic neurons are lost 
at both the focus and parafocus (Table IV). How- 
ever, it is unclear from these studies whether the 
seizures or the increased exposure to alumina gel 
is the cause of the loss of neurons in the parafocus 
of chronic monkeys. 
The magnitude of the percentage loss of GABA- 
ergic neurons and terminals reveals some interest- 
ing relationships (Table IV). The study by Houser 
et al.* showed that a decrease of GABAergic ter- 
minals ranged from 24 to 33% in chronically seiz- 
ing monkeys and from 14 to 22% in pre-seizing 
monkeys. The results of a previous study by Ribak 
et al.19 showed a more severe deficit range of 
GABAergic terminals in chronic animals. This lat- 
ter finding could have been due to the use of either 
chronically seizing monkeys with longer histories 
of seizures or thicker sections for counting than 
that used by Houser et al.*. The 2 studies that have 
analyzed the loss of GABAergic somata showed 
that the percentage loss of somata in chronic mon- 
keys (Table IV) is more similar to the percentage 
loss of terminals in the study by Ribak et a1.19. To- 
gether, these studies demonstrate a significant loss 
of GABAergic cells and terminals in the focus and 
parafocus of chronically seizing monkeys as well as 
at the site of alumina gel application in pre-seizing 
monkeys. They also indicate that the magnitude of 
these losses increases as the seizures develop. 
Thus, the GABAergic somata and terminals are 
decreased in number prior to the onset of clinical 
seizures and this decrease becomes more severe 
after seizure development. These findings add fur- 
ther support to the hypothesis that GABA loss 
plays a causal role in focal epilepsy. 
Two of our previous studies have provided data 
to determine which GABAergic cell types are af- 
fected most at chronic alumina gel epileptic foci. 
One study I8 showed that axosomatic synapses 
formed by the basket cell endings were severely 
lost. A subsequent studyI reported a significant 
loss of axon initial segment synapses formed by 
GABAergic chandelier cells. It is interesting to 
note that both chandelier and basket cell types do 
not co-localize neuropeptides because the 3 pep- 
tides (somatostatin, cholecystokinin, neuropep- 
tide Y) that are known to be co-localized to 
GABAergic neurons are found in other cortical 
cell types 7,23 Therefore, it is likely that most . 
GABAergic neurons lost at epileptic foci are using 
only GABA as a neurotransmitter. 
This study provides additional evidence to show 
that the GABAergic neuronal system is disrupted 
in some varieties of epilepsy. Biochemical studies 
of similarly treated monkeys have confirmed the 
loss of GAD activity in epileptic foci’. Similar 
losses have been shown for the GABA receptors’. 
Secondly, axosomatic symmetric synapses16, the 
type formed by terminals of GABAergic basket 
cells, have been shown to be reduced in number at 
experimental epileptic foci4.18*21, and terminals 
that form such symmetric synapses were shown to 
degenerate in pre-seizing monkeys’. Taken to- 
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gether with data from the present study that indi- 
cate that a selective loss of GABAergic neuronal 
somata occurs in pre-seizing monkeys at the site of 
the alumina gel granuloma, it is evident that dam- 
age to the cortical GABAergic inhibitory system is 
a common finding for experimental models of 
post-traumatic focal epilepsy. 
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